Management of Hypertriglyceridemia

Primary Causes and Contributing Factors

Excess body weight and visceral adiposity are primary drivers of hypertriglyceridemia, associated with reduced fatty acid oxidation in muscle tissue, according to the American College of Cardiology 1
Excessive alcohol consumption is a major contributor to hypertriglyceridemia, with even 1 ounce daily increasing triglycerides by 5-10%, as reported by the American College of Cardiology 1
High intake of simple carbohydrates and added sugars directly increases hepatic triglyceride production, with higher sugar intake raising triglycerides by approximately 10 mg/dL independent of body weight, according to the American College of Cardiology 1
Physical inactivity is strongly associated with elevated triglyceride levels, as noted by the American Academy of Family Physicians 2 and the American College of Cardiology 1
Uncontrolled diabetes mellitus is often the primary driver of severe hypertriglyceridemia, as poor glycemic control dramatically increases triglyceride production, according to the American College of Cardiology 2, 3, 1
Hypothyroidism contributes to disordered lipid metabolism, as reported by the American Academy of Family Physicians 2
Chronic kidney disease and nephrotic syndrome elevate triglyceride levels, according to the American Academy of Family Physicians 2 and the American College of Cardiology 1
Chronic liver disease disrupts triglyceride metabolism, as noted by the American Academy of Family Physicians 2 and the American College of Cardiology 1

The American College of Cardiology recommends classifying triglyceride levels by severity to determine appropriate treatment intensity and primary therapeutic goals, with normal levels being <150 mg/dL 1, 4
Mild hypertriglyceridemia is defined as 150-199 mg/dL, moderate as 200-499 mg/dL, severe as 500-999 mg/dL, and very severe as ≥1,000 mg/dL, according to the American Academy of Family Physicians 2 and the American College of Cardiology 1, 4
Mild to moderate hypertriglyceridemia increases cardiovascular disease risk, while severe and very severe levels (≥500 mg/dL) dramatically increase the risk of acute pancreatitis, with a 14% incidence at severe levels, as reported by the American Academy of Family Physicians 2 and the American College of Cardiology 1

For mild to moderate hypertriglyceridemia (150-499 mg/dL), the American College of Cardiology recommends initial management focusing on lifestyle modifications and cardiovascular risk reduction, with statins as first-line pharmacologic therapy when indicated 3, 1
Target 5-10% body weight reduction, which produces a 20% decrease in triglycerides, according to the American College of Cardiology 3, 1, 4
Restrict added sugars to <6% of total daily calories, as recommended by the American College of Cardiology 3, 1
Limit total dietary fat to 30-35% of total calories, prioritizing polyunsaturated and monounsaturated fats over saturated fats (<7% of calories), according to the American College of Cardiology 3, 1
Consume ≥2 servings (8+ ounces) per week of fatty fish rich in omega-3 fatty acids, as recommended by the American College of Cardiology 1
Engage in ≥150 minutes/week of moderate-intensity aerobic activity, which reduces triglycerides by approximately 11%, according to the American College of Cardiology 3, 1, 4
Limit or completely avoid alcohol consumption, with complete abstinence recommended for severe hypertriglyceridemia, as advised by the American College of Cardiology 3, 1, 4

Fenofibrate 54-160 mg daily is the drug of choice for severe hypertriglyceridemia (≥500 mg/dL), providing 30-50% triglyceride reduction, according to the American Academy of Family Physicians 2 and the American College of Cardiology 3, 1, 4
Icosapent ethyl (pure EPA) 2g twice daily is indicated as adjunct to maximally tolerated statin therapy for patients with triglycerides ≥150 mg/dL and established cardiovascular disease or diabetes with ≥2 additional risk factors, as recommended by the American College of Cardiology 3, 1, 4
Statins are first-line for moderate hypertriglyceridemia (200-499 mg/dL) when cardiovascular risk is elevated, providing 10-30% dose-dependent triglyceride reduction, according to the American College of Cardiology 3, 1, 4

Reassess fasting lipid panel in 6-12 weeks after implementing lifestyle modifications, as recommended by the American College of Cardiology 1, 4
Reassess lipids 4-8 weeks after initiating or adjusting pharmacotherapy, according to the American College of Cardiology 3, 1
Monitor liver function tests and creatine kinase if fibrates are added, particularly at baseline and 3 months after initiation, as advised by the American College of Cardiology 3, 1